- TG Therapeutics press release (TGTX): Q3 EPS of $2.43 may not be comparable to consensus of $0.21.
- Third quarter results include a non-recurring income tax benefit of approximately $365.0 million, driven by the release of our deferred tax asset valuation allowance.
- Revenue of $161.71M (+92.8% Y/Y) beats by $9.54M.
- Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million
-
2025 Financial Guidance
- Raises BRIUMVI U.S. net product revenue target to approximately $585 million for the full year 2025 (prior guidance of $570 – $575 million for full year 2025)
- Raises total global revenue target to approximately $600 million vs $587.51M consensus for the full year 2025 (prior guidance of $585 million for full year 2025)
- Shares +10% PM.
TG Therapeutics EPS of $2.43, revenue of $161.71M beats by $9.54M
